Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-08-30 Management Reports
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management Discussion & Analysis” for the period ended June 30, 2025. It contains management’s detailed discussion of financial performance, results of operations, liquidity and capital resources, risks, and forward-looking statements, consistent with a standalone MD&A. This matches the definition of a Management Report (MDA).
2025-08-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive set of interim financial statements for NAVCO Pharmaceuticals Inc. for the period ended June 30, 2025. It includes a Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Equity, Statement of Cash Flows, and detailed Notes to the Financial Statements. It is not an announcement or a summary, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). Q4 2025
2025-08-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by the CEO, which is a regulatory certification form accompanying the interim financial report and MD&A under Canadian NI 52-109. It does not itself contain financial results or MD&A narrative (so it’s not the interim report (IR)), nor is it a dividend notice, earnings release, or management discussion. It is a mandatory regulatory filing/certificate form, with no substantive report attached but rather a compliance certification. Therefore, it best fits the fallback category “Regulatory Filings” (RNS).
2025-08-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by the CFO under NI 52-109, attesting to the accuracy of the interim financial report and MD&A. It is not itself the interim report (IR) or an audit report (AR), nor an earnings release or other financial disclosure. It is a regulatory attestation filing required by securities legislation, fitting the general Regulatory Filings category (RNS).
2025-08-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 Certification of Interim Filings (a regulatory certificate by the CEO certifying the interim financial report and MD&A for the period ended March 31, 2025 under NI 52-109). It is not the interim report itself (IR), nor an earnings release or MD&A narrative, but rather a regulatory compliance filing. Thus it falls under the general “Regulatory Filings” category (RNS).
2025-05-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Certification of Interim Filings' (Form 52-109FV2) signed by the CFO. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like an interim report), must be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements or substantive financial data. Q1 2025
2025-05-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.